Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018

Jan. 25, 2012 - PRLog -- GlobalData estimates that the global peptic ulcer therapeutics market was worth $892.4m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to $1,046.2m by 2018. Peptic ulcers develop due to two main factors: infection with Helicobacter pylori (H. pylori) and the long-term use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). H. pylori infection accounts for almost 85% of all peptic ulcer cases. The peptic ulcer market is well served by Proton Pump Inhibitors (PPIs), which form the majority. PPIs include omeprazole, lansoprazole, pantoprazole, Nexium (esomeprazole) and Aciphex
(rabeprazole); and histamine blockers such as ranitidine, nizatidine, famotidine and cimetidine. Omeprazole is currently the most widely prescribed drug for peptic ulcers across the seven major markets. It is available as a generic and an Over-The-Counter (OTC) drug, making it cost-effective. Between 2005 and 2010, the market grew at a CAGR of 2.8%, largely due to the lack of new drug launches and the entry of OTC versions of omeprazole and lansoprazole. The patent expiry of Prevacid
(lansoprazole) in the US in 2009 did not impact the market significantly due to its small patient share within the US market.

Between 2010 and 2018, the global peptic ulcer market is expected to grow at a CAGR of 2%. During this period, Nexium (esomeprazole) and Aciphex (rabeprazole), both of which are PPIs, will lose their patent exclusivity. The patent for Nexium is set to expire in the US in 2015 and in Europe and Japan in 2014 and the patent for Aciphex will expire in the US in 2013. This is likely to be marginally compensated by the entry of new products. These new drugs include Vimovo, (naproxen/esomeprazole magnesium) launched in the US in 2010 and expected to enter the European markets in 2012; Axanum (aspirin/ esomeprazole), expected to be available in Europe by 2012; and PA32540 (aspirin/omeprazole) expected to be launched in the US by 2014 and in Europe by 2015. Vimovo, Axanum and PA32540, all are fixed-dose combinations containing an NSAID and a PPI. These drugs target NSAID-induced peptic ulcers. Therefore, their entry will positively impact the NSAID-induced peptic ulcer market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

Peptic ulcer treatment relies on the use of PPIs and histamine blockers, although PPIs are most widely prescribed. PPI-based triple therapy (a combination of one PPI and two antibiotics) is the preferred approach for the treatment of H. pylori-induced peptic ulcers. PPIs are also used in the healing and risk reduction of NSAID-induced peptic ulcers. Although antihistamines have long been prescribed to treat ulcers, they are less effective than PPIs, of which omeprazole, lansoprazole, pantoprazole, Nexium and Aciphex are currently prescribed. Aciphex is under patent protection until 2013 and Nexium until 2014.

GlobalData, the industry analysis specialist, has released its new report, “Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global peptic ulcer market. The report identifies the key trends shaping and driving the global peptic ulcer market. It also provides an insight into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global peptic ulcer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Pept...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.